Media coverage about Protagonist Therapeutics (NASDAQ:PTGX) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Protagonist Therapeutics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.520510999028 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have impacted Accern’s scoring:

Several equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research report on Tuesday. BidaskClub downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. BMO Capital Markets restated an “outperform” rating and issued a $42.00 target price (down previously from $44.00) on shares of Protagonist Therapeutics in a research report on Thursday, March 8th. Finally, Stifel Nicolaus assumed coverage on Protagonist Therapeutics in a research report on Monday, January 29th. They issued a “buy” rating and a $32.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $34.00.

Protagonist Therapeutics (NASDAQ:PTGX) opened at $20.67 on Wednesday. Protagonist Therapeutics has a 1 year low of $8.00 and a 1 year high of $23.97. The company has a market capitalization of $395.77 and a P/E ratio of -9.57.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, March 7th. The company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.19. The company had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $8.75 million. analysts expect that Protagonist Therapeutics will post -1.3 earnings per share for the current fiscal year.

In related news, insider David Y. Liu sold 3,500 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $21.29, for a total transaction of $74,515.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Thomas P. O’neil sold 8,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.00, for a total value of $160,000.00. Following the transaction, the chief financial officer now owns 4,000 shares in the company, valued at approximately $80,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 19,444 shares of company stock worth $394,354. 15.50% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Protagonist Therapeutics (PTGX) Stock Price” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with's FREE daily email newsletter.